A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

NCT06256549 on ClinicalTrials.gov · last registry update 2024-02-23

An unusually large phase 2: 272 participants, more than double the 110 typical for the stage. Its estimated completion date, 20 July 2024, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Gan and Lee Pharmaceuticals, USA
Sponsor type: Industry
Enrollment: 272
Started: 2023-08-09
Primary completion: 2024-07-20 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Compared with Semaglutide, the changes of HbA1c compared with baseline after continuous administration of GZR18 injection for 24 weeks

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.